Oppenheimer Reaffirms Outperform Rating for Chemomab Therapeutics (NASDAQ:CMMB)

Chemomab Therapeutics (NASDAQ:CMMB)‘s stock had its “outperform” rating restated by equities research analysts at Oppenheimer in a research report issued on Friday,Benzinga reports. They presently have a $11.00 price target on the stock, down from their previous price target of $13.00.

Chemomab Therapeutics Trading Down 3.7 %

NASDAQ:CMMB opened at $1.68 on Friday. The stock has a market capitalization of $24.05 million, a PE ratio of -1.68 and a beta of 0.53. Chemomab Therapeutics has a 1-year low of $0.42 and a 1-year high of $2.55. The firm has a fifty day simple moving average of $1.56 and a 200 day simple moving average of $1.28.

Chemomab Therapeutics (NASDAQ:CMMB) last released its quarterly earnings data on Wednesday, August 21st. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.06). During the same period in the prior year, the business posted ($0.72) EPS. On average, equities analysts predict that Chemomab Therapeutics will post -0.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Sphera Funds Management LTD. acquired a new position in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned approximately 8.46% of Chemomab Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).